| Symbol | MGX |
|---|---|
| Name | METAGENOMI, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | 5959 HORTON STREET,7TH FLOOR, EMERYVILLE, California, 94608, United States |
| Telephone | +1 510 871-4880 |
| Fax | — |
| — | |
| Website | https://metagenomi.co |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001785279 |
| Description | At Metageno-mi, we are cre-at-ing poten-tial-ly cura-tive ther-a-peu-tics using our metage--nomics-pow-ered genome edit-ing toolbox.We believe tools with capa-bil-i-ties that go beyond the cur-rent tech-nol-o-gy land-scape will be required in order to reach the full ther-a-peu-tic poten-tial of genome edit-ing. By har-ness-ing the pow-er of metage-nomics, the study of genomes recov-ered from uncul-ti-vat-ed organ-isms in the nat-ur-al envi-ron-ment, we are dis-cov-er-ing and devel-op-ing a suite of nov-el genome edit-ing tools with the poten-tial to make any desired ther-a-peu-tic gene edit, any-where in the human genome. Additional info from NASDAQ: Additional info from NASDAQ: |
Metagenomi Therapeutics Reports Business Updates and First Quarter 2026 Financial Results
Read moreNew Form ARS - Metagenomi Therapeutics, Inc. <b>Filed:</b> 2026-04-27 <b>AccNo:</b> 0001193125-26-182345 <b>Size:</b> 4 MB
Read moreNew Form DEFA14A - Metagenomi Therapeutics, Inc. <b>Filed:</b> 2026-04-27 <b>AccNo:</b> 0001193125-26-182339 <b>Size:</b> 1 MB
Read moreNew Form DEF 14A - Metagenomi Therapeutics, Inc. <b>Filed:</b> 2026-04-27 <b>AccNo:</b> 0001193125-26-182325 <b>Size:</b> 2 MB
Read moreMetagenomi Therapeutics, Inc. Announces Publication in Nature Structural & Molecular Biology Highlighting Proprietary Compact CRISPR Nuclease with Enhanced Genome Editing Efficiency
Read moreIrish Jian 🟢 acquired 322.0K shares (1 derivative) of Metagenomi Therapeutics, Inc. (MGX) at $1.34 Transaction Date: Apr 01, 2026 | Filing ID: 141946
Read moreWein Matthew 🟢 acquired 79.0K shares (1 derivative) of Metagenomi Therapeutics, Inc. (MGX) at $1.34 Transaction Date: Apr 01, 2026 | Filing ID: 141914
Read moreWapnick Pamela 🟢 acquired 168.0K shares (1 derivative) of Metagenomi Therapeutics, Inc. (MGX) at $1.34 Transaction Date: Apr 01, 2026 | Filing ID: 141867
Read moreMetagenomi Therapeutics Reports Business Updates and Full Year 2025 Financial Results
Read more